<DOC>
	<DOC>NCT02524678</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, PK and PD of URC102 in healthy subjects.</brief_summary>
	<brief_title>Phase 1 Study(Additional) of URC102 in Healthy Subjects</brief_title>
	<detailed_description>Tolerability, safety, and pharmacokinetics (PK) of URC102 will be assessed after 7-day repeated oral dose in healthy adult Korean males. In addition, pharmacodynamic (PD) response of blood and urinary uric acid levels will be assessed.</detailed_description>
	<criteria>Healthy male volunteers Participated in other clinical study within past 3 months prior to receiving an IP administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>